Primary Ciliary Dyskinesia - Epidemiology Forecast to 2028

Primary Ciliary Dyskinesia - Epidemiology Forecast to 2028

  • September 2019 •
  • 60 pages •
  • Report ID: 5816573 •
  • Format: PDF
‘Primary Ciliary Dyskinesia - Epidemiology Forecast to 2028’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Primary Ciliary Dyskinesia in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.

Geography Covered

• The United States
• EU5 (Germany, France, Italy, Spain and the United Kingdom)
• Japan

Study Period: 2017–2028

Primary Ciliary Dyskinesia - Disease Understanding and Treatment Algorithm

The Primary Ciliary Dyskinesia (PCD) market report gives the thorough understanding of the Primary Ciliary Dyskinesia (PCD) by including details such as disease definition, causes, symptoms, pathophysiology, and diagnostic trends. It also provides overview of treatment and management of the disease in the US, EU5 and Japan.
Primary ciliary dyskinesia (PCD) is an autosomal recessive genetic disorder caused by the impaired function of cilia of the respiratory tract epithelial cells, which may also involve other ciliated cells in the reproductive system of the male or female.

Primary Ciliary Dyskinesia (PCD) Epidemiology

The Primary Ciliary Dyskinesia epidemiology division provide the insights about historical and current patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and the prevalence based on clinical manifestations in the US, EU5 and Japan.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total diagnosed prevalent cases, and prevalence based on clinical manifestations) scenario of Primary Ciliary Dyskinesia in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017–2028.
According to the analyst, total prevalent population of Primary Ciliary Dyskinesia in seven major markets was found to be 80,815 in 2017.

Primary Ciliary Dyskinesia (PCD) Report Insights

• The report covers detailed overview of Primary Ciliary Dyskinesia explaining its causes, symptoms, pathophysiology, diagnosis and treatment patterns.
• The report provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, and UK) and Japan.
• The Report highlights the unmet needs of Primary Ciliary Dyskinesia (PCD).
• The Report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
• The report provides the segmentation of the disease epidemiology by total diagnosed prevalent patient population and clinical manifestations in 7MM.

Primary Ciliary Dyskinesia (PCD) Report Key Strengths

• 10 Year Forecast
• 7MM Coverage
• Total diagnosed prevalent cases
• Prevalence of PCD based on Clinical Manifestations

Primary Ciliary Dyskinesia (PCD) Report Assessment

• Patient Segmentation based on clinical manifestations
• Disease Risk & Burden
• Factors driving growth in a specific patient population